1-Butoxy-5-methylphthalazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1-Butoxy-5-methylphthalazine
• 化学式: C₁₃H₁₆N₂O
• 分子量: 216.28
• InChiKey: BVUQGPNKRXZJHK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• ALKOXY-SUBSTITUTED COMPOUNDS, METHODS, AND COMPOSITIONS FOR INHIBITING PARP ACTIVITY
  申请人：GUILFORD PHARMACEUTICALS INC.

  公开号：EP1012145A1

  公开（公告）日：2000-06-28
• USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES
  申请人：DelMar Pharmaceuticals, Inc.

  公开号：US20180071244A1

  公开（公告）日：2018-03-15

  The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of malignancies of the central nervous system in pediatric patients, including glioblastoma multiforme (GBM) high grade glioma, and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N 7 methylation and that can induce double-stranded breaks in DNA. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents (e.g. cisplatin) and can possess additive or super-additive effects.
• USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER
  申请人：Bacha Jeffrey A.

  公开号：US20190091195A1

  公开（公告）日：2019-03-28

  Substituted hexitol derivatives such as dianhydrogalactitol are useful in the treatment of various neoplastic pathologies. Said pathologies include glioblastoma multiforme, non-small-cell lung carcinoma (NSCLC), ovarian cancer, and leptomeningeal carcinomatosis. The anti-neoplastic activity of dianhydrogalactitol is demonstrated to be due to its activity as an alkylating agent that creates N 7 methylation and inter-strand DNA crosslinks. The hexitol derivatives may be used alone or in combination with other anti-neoplastic agents.
• [EN] ALKOXY-SUBSTITUTED COMPOUNDS, METHODS, AND COMPOSITIONS FOR INHI BITING PARP ACTIVITY<br/>[FR] COMPOSES A SUBSTITUTION ALCOXY, PROCEDES ASSOCIES, ET COMPOSITIONS D'INHIBITION DE L'ACTIVITE DE LA POLY(ADENOSINE 5'-DIPHOSPHO-RIBOSE) POLYMERASE
  申请人：GUILFORD PHARMACEUTICALS INC.

  公开号：WO1999011628A1

  公开（公告）日：1999-03-11

  (EN) A compound, compositions, methods of use, and processes of making formula (I) or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein: R1, when present, is hydrogen or lower alkyl; R2 is a lower alkyl, aryl, aralkyl, lower alkanoyl, or -(CH2)n-(CHOH)y(CH2)mA, wherein n is 1-4, y is 0 or 1, m is 0-5, and A is cycloalkyl, cycloalkenyl, lower alkanoyl, aryl, aralkyl, -NH2, -NH-(lower alkyl), (a), (b), (c), or (d); Y represents the atoms necessary to form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic; Z is (i) -CHR2CHR3- where R2 and R3 are independently hydrogen, alkyl, aryl or aralkyl; (ii) -R6C=CR3- where R6 and R3 are independently hydrogen, lower alkyl, aryl, aralkyl chlorine, bromine or -NR7R8, where R7 and R8 are independently hydrogen or lower alkyl, or, R6 and R3, taken together, form a fused 5- to 6-membered ring that is aromatic or nonaromatic and carbocyclic or heterocyclic; (iii) -R2C=N-; (iv) -CR2(OH)-NR7-; or (v) -C(O)-NR7-.(FR) L'invention concerne un composé correspondant à la formule (I), des compositions, des méthodes d'utilisation et des procédés de fabrication de ces composés, d'un sel, hydrate, ester, solvate, promédicament, métabolite stéréo-isomère ou de mélange de ceux-ci, acceptables sur le plan pharmacologique. Dans cette formule, R1, lorsqu'il est présent, représente hydrogène ou alkyle inférieur, R2 représente alkyle inférieur, aryle, aralkyle, alcanoyle inférieur, ou -(CH2)n-(CHOH)y(CH2)mA, où n vaut 1-4, y vaut 0 ou 1, m vaut 0-5 et A représente cycloalkyle, cycloalcényle, alcanoyle inférieur, aryle, aralkyle, -NH2, -NH-(alkyle inférieur), (a), (b), (c), ou (d), Y représente les atomes nécessaires à la formation d'un noyau condensé possédant 5 à 6 chaînons et qui est aromatique ou non aromatique et carbocyclique ou hétérocyclique, Z représente (i) -CHR2CHR3- où R2 et R3 représentent indépendamment hydrogène, alkyle, aryle ou aralkyle; (ii) -R6C=CR3- où R6 et R3 représentent indépendamment hydrogène, alkyle inférieur, aryle, aralkyle, chlore, brome ou -NR7R8, où R7 et R8 représentent indépendamment hydrogène ou alkyle inférieur, ou bien R6 et R3, pris ensemble, forment un noyau condensé à 5 ou 6 chaînons qui est aromatique ou non aromatique et carbocyclique ou hétérocyclique, (iii) -R2C=N, (iv) -CR2(OH)-NR7-, ou (v) -C(O)-NR7-.
• [EN] USE OF DIANHYDROGALACTITOL OR DERIVATIVES AND ANALOGS THEREOF FOR TREATMENT OF NON-SMALL-CELL LUNG CARCINOMA, GLIOBLASTOMA, AND OVARIAN CARCINOMA BY INDUCTION OF DNA DAMAGE AND STALLING OF CELL CYCLE<br/>[FR] UTILISATION DE DIANHYDROGALACTITOL OU DE DÉRIVÉS ET D'ANALOGUES DE CELUI-CI POUR LE TRAITEMENT D'UN CARCINOME NON À PETITES CELLULES, D'UN GLIOBLASTOME ET D'UN CARCINOME DE L'OVAIRE PAR INDUCTION DE LÉSIONS DE L'ADN ET BLOCAGE DU CYCLE CELLULAIRE
  申请人：DEL MAR PHARMACEUTICALS

  公开号：WO2017042634A2

  公开（公告）日：2017-03-16

  The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma, non-small-cell lung carcinoma (NSCLC) and ovarian cancer, as well as other types of malignancy, including brain metastases of NSCLC. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation and inter-strand crosslinks that can induce double-stranded breaks in DNA. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents and can possess additive or synergistic effects. Dianhydrogalactitol can be used for treatment of leptomeningeal carcinomatosis.